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                                                              ABSTRACT
Partial or non-response to antidepressants in Generalized Anxiety Disorder (GAD) is common in 
clinical settings, and adjunctive biological interventions may be required. Adjunctive herbal and 
nutraceutical treatments are a novel and promising treatment option. L-theanine is a non-protein 
amino acid derived most-commonly from tea (Camellia sinensis) leaves, which may be beneficial 
in the treatment of anxiety and sleep disturbance as suggested by preliminary evidence. We 
conducted a 10-week study (consisting of an 8-week double-blind placebo-controlled controlled 
period, and 1-week pre-study and 2-week post-study single-blinded observational periods) 
involving 46 participants with a DSM-5 diagnosis of GAD. Participants received adjunctive L-
theanine (450-900mg) or matching placebo with their current stable antidepressant treatment, 
and were assessed on anxiety, sleep quality, and cognition outcomes. Results revealed that 
adjunctive L-theanine did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) 
nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35). However, LT treated 
participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015). 
Further, a separation in favour of L-theanine was noted on the ISI in those with non-clinical levels 
of insomnia symptoms (ISI ≤ 14; p = 0.007). No significant cognitive effects (trail making time 
and the modified emotional Stroop) were revealed. While this preliminary study did not support 
the efficacy of L-theanine in the treatment of anxiety symptoms in GAD, further studies to explore 
the application of L-theanine in sleep disturbance are warranted. 
Keywords: L-theanine; anxiety; sleep; GAD; randomized controlled trial
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Introduction
Effective first-line treatments for Generalized Anxiety Disorder (GAD) include psychotherapy 
such as Cognitive Behavioural Therapy (Carpenter et al., 2018) and pharmacotherapies such 
as antidepressants and anxiolytic agents (Reinhold and Rickels, 2015). With antidepressant 
treatments, the remission rates typically are in the realm of 30-50% (Reinhold et al., 2011). 
As such, adjunctive agents (such as benzodiazepines, pregabalin and/or antipsychotics) are 
often used to enhance the effectiveness of antidepressants in those who are non-responsive 
(Latas et al., 2018). A common co-occurrence with GAD is insomnia (Ferre Navarrete et al., 
2017), and subjectively reported sleep disturbance is an important part of GAD symptomology 
(Cox and Olatunji, 2016). Nutraceuticals and ‘phytoceuticals’, pharmaceutical grade nutrients 
or plant-based compounds with bioactive effects, are increasingly being considered as novel 
adjunctive options in psychiatric disorders, due to their potential efficacy and acceptable 
tolerability (Sarris et al., 2016, 2010).  
L-theanine (n-ethylglutamic acid; LT) is a non-proteinogenic amino acid derived almost 
exclusively from tea leaves (Camellia sinensis), with the highest concentrations found in green, 
oolong, and Pu-erh tea (Syu et al., 2008). A natural ethylamide analogue of glutamate, 
preclinical studies have found LT to pass freely through the blood-brain barrier, reduce 
presynaptic glutamate release (Kakuda et al., 2008), increase inhibitory neurotransmitter 
GABA, and enhance glycine and dopamine release (Kakuda et al., 2008; Kimura and Murata, 
1971; Shen et al., 2011; Yamada et al., 2007, 2005). Although the direct effects of LT on GABA 
pathways is not well understood, a recent study has shown differential decreases of cortical 
and hippocampal GABA in mouse models (Schallier et al., 2013). A comprehensive review of 
LT’s neuropharmacology has also highlighted its neuroprotective effects, as well as the ability 
to increase alpha wave brain activity (Lardner, 2014). Alpha brain-activity is a measure of 
wakeful relaxation and has been associated with creativity, improved concentration, and 
decreased anxiety (Lardner, 2014).  Owing to its influence on inhibitory neurotransmission, as 
well as promotion of alpha brain wave activity, LT has been investigated in animal models of 
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anxiety, demonstrating anxiolytic as well as antidepressant activity (Ogawa et al., 2018; Unno 
et al., 2013a; Wakabayashi et al., 2012).
While preclinical and clinical evidence (covered in the Discussion) suggests that LT has 
anxiolytic and hypnotic properties, clinical trials investigating its therapeutic effects in anxiety 
disorders are lacking. Further, there is a deficit of augmentation studies in GAD, and no studies 
have investigated the potential usefulness of different doses of LT.   Thus our current study 
aimed to elucidate the efficacy and safety of adjunctive LT in the treatment of GAD, with an a 
priori hypothesis that the compound would reduce participant’s anxiety and insomnia severity. 
An additional aim was to assess whether a titrated high dose of LT (900mg/day) is needed in 
cases of non-response to the initial 450mg/day dose. 
Methods
Overview
This was a phase II, randomised, double-blind, placebo controlled, multi-centre pilot study 
comparing adjunctive LT to adjunctive placebo in individuals with GAD who were non-
responsive to their current antidepressant. The study was conducted between 2016 – 2018 
and study sites were located in Australia at The Melbourne Clinic (Richmond, Melbourne), The 
Royal Brisbane and Womens Hospital (Herston, Brisbane) and NICM Health Research Institute 
(Campbelltown, New South Wales). The trial was registered on the Australian New Zealand 
Clinical Trials Registry (ANZCTR # 12616000759493) on 9th June 2016, and Human Research 
Ethics Committee approvals obtained from each trial site to conduct the study (TMCREC 273; 
UQ MREC 2016000774; WSU HREC H12268). 
Eligibility criteria
Eligible participants met the following criteria: aged between 18-75 years; primary diagnosis 
of GAD at study entry (DSM-V; confirmed via the MINI International Neuropsychiatric Interview 
version 6.0 [MINI 6.0] and Hamilton Anxiety Rating Scale [HAMA] score ≥16); taking an 
antidepressant medication at a stable dose for minimum four-weeks at a therapeutic dose for 
GAD. Women were required to use adequate contraception throughout the study period. 
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Participants were excluded if they were experiencing a current episode of depression (as per 
MINI 6.0 or ≥18 Montgomery-Asberg Depression Scale [MADRS] score); diagnosis of Bipolar 
or Psychotic Disorder/s (self-reported by the participant, as per their treating doctor, or as per 
MINI 6.0); current alcohol or substance abuse (as per MINI 6.0); recently commenced 
psychotherapy (acceptable if stable for more than four weeks); known or suspected clinically 
unstable medical conditions; consumption of more than three cups of tea per day (due to 
presence of LT in tea); presenting with suicidal ideation at baseline (>3 on MADRS suicidal 
thoughts domain); three or more failed antidepressant trials for the current episode of GAD; 
pregnancy or breastfeeding. Participants were withdrawn from the study if they: elected to 
change their current antidepressant or psychotherapy program; initiated new treatment/s 
outside the study protocol; had a MADRS score >23 at any time point after baseline; ceased 
adequate contraception methods or fell pregnant; experienced a serious adverse event or 
newly diagnosed medical conditions which the medical investigator/s deemed necessary for 
them to withdraw.  
Measures
Due to the two major hypothesis-driven clinical areas of inquiry (anxiety and insomnia), we 
used dual primary outcome measures: the Hamilton Anxiety Rating Scale (HAMA) was 
administered according to the Structured Interview Guide for the Hamilton Anxiety Scale 
(SIGHA) for the anxiety outcome (Hamilton, 1959), and the Insomnia Severity Index (ISI) for 
the insomnia outcome (Morin et al., 2011). Secondary outcome measures included the MADRS 
(Montgomery and Asberg, 1979), a clinician reported measure of depression severity, the Beck 
Anxiety Inventory (BAI) (Beck et al., 1988), Penn State Worry Questionnaire (PSWQ) (Meyer 
et al., 1990) and World Health Organisation Quality of Life-BREF (WHOQOL-BREF) (The 
WHOQOL GROUP, 1998). A trail making task (measuring time in seconds to complete task) 
was used to determine the effect of LT on cognition. A modified emotional Stroop task was also 
undertaken in which participant’s response times to name colours of positive, neutral and 
anxiety-related words (such as stroke, debts, crazy) was measured. The self-reported 
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Systematic Assessment for Treatment Emergent Effects (SAFTEE)  was used to assess for the 
presence and severity of adverse events (Levine and Schooler, 1986). The WHOQOL-BREF, 
trail making time and the modified emotional Stroop were completed at baseline and Week-8. 
All other measures were completed at each time point. 
Treatment Intervention 
Eligible participants were initially randomised, via independent computer-generated block 
randomisation to receive, in addition to their current antidepressant, LT at 450mg per day 
(given as one 225mg capsule twice per day, or placebo matched for appearance, taste, and 
scent) for the first four weeks of the study. Participants who did not achieve a ≥35% reduction 
in their baseline HAMA score at Week-4 were titrated to two capsules, twice per day (900mg 
LT per day, or matching placebo) for the remaining four weeks of the treatment intervention 
phase. Titration at Week-4 is in line with flexible dosing seen in clinical practice where some 
patients, due to individual pharmacokinetic and pharmacodynamic differences, require a higher 
dose to achieve response. Participants ceased taking capsules for the last two weeks of the 
study (from Week-8 to Week-10) which was used to monitor for any potential ongoing 
therapeutic activity or withdrawal effect from the LT.
Procedures                                                                                                                                                                                                                        
The study was advertised via social media, on anxiety support group webpages and outpatient 
clinics (e.g. flyers distributed in psychology and GP clinics). Enquiring individuals were initially 
telephone screened by psychology or mental health qualified research staff to determine if 
basic criteria were met. If so, they were invited to attend a baseline screening session where 
informed consent was obtained. Demographics, MINI 6.0 (for psychiatric diagnoses) and 
medical history were then assessed, and outcome assessments were conducted. At Week-1 
(true randomisation baseline), a phone interview was conducted where the HAMA was 
administrated to determine persistence of anxiety symptoms. If the participant remained 
eligible (HAMA ≥16 and ≤35% reduction in HAMA score), their allocated treatment was posted 
(containing 30 capsules) with written dosage instructions. Participants were instructed to take 
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one capsule (two if titrated from Week-4 onwards) in the morning and one capsule (two if 
titrated from Week-4 onwards) in the afternoon/early evening. Dose instructions to participants 
were nonspecific as whether to take the capsules with food. Participants attended follow-up 
visits at Week-2, 4, 6 and 8 where the HAMA, MADRS, BAI, PSWQ, ISI, and SAFTEE were 
completed (WHOQOL-BREF, cognition and modified Stroop assessments were also completed 
at Week-8). Drug use, alcohol, caffeine and tea consumption was also recorded at each visit. 
At Week-10 (conducted two weeks after IP washout) only the HAMA, MADRS and SAFTEE were 
completed. Additional capsules were dispensed each fortnight (30-60 capsules, depending on 
titration schedule) and participants were asked to return any remaining capsules at each 
follow-up visit to determine compliance. Participants were reimbursed $10 in the form of 
department/food store gift vouchers for each appointment visit they attended (to cover travel 
expenses) and were also provided with LT samples (2x 30 capsule bottles, each capsule 
containing 225mg LT) at Week-10. 
Statistical analysis 
Sociodemographic variables were tested for between-group differences using t-tests for 
continuous variables and Chi-squared tests for categorical variables. Primary and secondary 
measures were assessed for change across time utilising Linear Mixed effects Models (LMMs). 
LMMs included main effects of Time, Group and a Group x Time interaction. A random effect of 
subject (Site x Participant) and random intercept was also included. A random slope was 
included depending on results of the Wald test and Bayesian Information Criterion (BIC). 
Covariance structure was chosen based on visual inspection of the data and inspection of BIC. 
Models are presented unadjusted unless clearly stated. Adjusted models included covariates 
such as trial site, titration, age, gender, current treatments and caffeine intake. Only covariates 
which had significant main effects were retained in adjusted models. Primary analysis of the 
data was conducted with blinding to group allocation. Tests of significance were conducted 
using a two-sided alpha level of 0.05. Data was analysed using the Statistical Package for 
Social Sciences software (SPSS, version 24.0, IBM, Chicago). 
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                                ………………………………….. Figure 1 About Here ………………………………
RESULTS
Sample and Participant Characteristics
After screening and baseline exclusions (Figure 1), a total sample size of 46 participants was 
available for analysis. There were 19 participants who completed the Week-8 visit (86.4%) in 
the active group, compared to 18 (73.9%) in the placebo group χ2(1,46) = 0.942, p = 0.34. 
In a per protocol analysis, one participant’s data was excluded due to treatment non-
adherence and another participant had their Week-8 data excluded, also due to non-
adherence (<60% adherence). The remaining participants in the study (n = 44) achieved at 
least 70% adherence based on returned capsule counts. Finally, data collected subsequent to 
Week-4 was removed from two participants due to protocol deviations (change of 
antidepressant and psychotherapy, respectively). 
Demographic and clinical characteristics of the full sample are displayed in Table 1. Concurrent 
psychotherapy was significantly more frequent in the LT group (73%) than the placebo group 
(35%), χ2(1,45) = 6.51, p = 0.011. The mean age was significantly higher in the LT group 
(40.7 ± 15.0) than in the placebo group (32.2 ± 9.29), t(1,43) = -2.26, p = 0.029. 
                     ……………………… Table 1, 2, and Figure 2 and 3 About Here …………………..…
Primary outcomes (anxiety and insomnia) 
Baseline and change scores for primary and secondary models are displayed in Table 2. 
Groups were matched on each measure except for the BAI, in which self-reported anxiety was 
more severe in the LT group (25.00 + 9.58) than the placebo group (20.3 + 9.11), with a 
trend towards significance, t(40) = -1.73, p = 0.092. On the HAMA, a significant effect for 
Time was revealed, indicating an overall reduction in anxiety across time in the pooled sample, 
F(1,162) = 44.2, p < 0.001. However, a non-significant Group x Time interaction indicated 
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no significant additional effect of LT treatment, F(1,162) = 0.78, p = 0.38. In adjusted models, 
none of the investigated covariates altered this relationship or demonstrated an interaction 
with Group and/or Time. No change in anxiety was found when LT administration was ceased 
when comparing endpoint HAMA score (Week 8; 14.59 ± 6.00) to post washout HAMA score 
(Week 10; 14.00 ± 5.71) in the LT group only, t(16) = -0.34, p = 0.74. 
On the ISI, a non-significant trend for Time on LMMs suggested improvement over time in the 
pooled sample, F(1, 52) = 3.11, p = 0.084. Subsequent to Week-2, the LT group showed 
lower insomnia symptoms relative to the placebo group at each visit, although this was not 
reflected in a significant Group x Time interaction, F(1,52) = 0.90, p = 0.35. Considering only 
participants with ‘clinical insomnia’ (baseline ISI score >14; n = 18), there was similarly no 
significant treatment-effect noted, F(1,64) = 2.17, p = 0.15. However, in patients who did 
not meet criteria for clinical insomnia (baseline ISI score ≤ 14; n = 25), a significant 
treatment-effect was noted in favour of LT, F(1,84) = 7.52, p = 0.007. No correlation between 
change in HAMA score and change in ISI score was noted in the LT group, indicating that any 
benefit to sleep was not secondary to reduced anxiety (r = 0.174, p = 0.49). Finally, in the 
LT group alone, change in ISI score was significantly correlated with HAMA score at baseline 
(r = -0.51, p = 0.031), indicating that response on the ISI may depend on baseline anxiety 
severity. 
Each of the items of the ISI were investigated individually to further investigate the role of LT 
in insomnia. A significant treatment effect was found only for item 4 “How 
SATISFIED/DISSATISFIED are you with your CURRENT sleep pattern?”, in which LT 
significantly improved subjective sleep satisfaction, F(1,154) = 6.08, p = 0.015. Further, 
considering only participants without clinical insomnia (baseline ISI score ≤ 14), significant 
treatment effects in favour of LT were found for item 1 “Difficulty falling asleep” (p = 0.049), 
item 3 “Problems waking up too early” (p = 0.017), item 4 (p < 0.001) and item 7 “To what 
extent do you consider your sleep problem to INTERFERE with your daily functioning…” (p = 
0.030). 
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Secondary outcomes
The Group x Time interaction on the MADRS (F[1,84] = 0.817, p = 0.37), BAI (F[1,153] = 
0.815, p=.37) and the PSWQ (F[1,152] = .010, p= 0.92) were found to be non-significant. 
Trail making time, as well as neutral, positive and anxiety card completion time on the 
modified emotional Stroop also showed no separation between groups (data not shown; all p 
> 0.05).  After adjusting for covariates, results remained unchanged in each model. Finally, 
there was no evidence that caffeine intake interacted with LT treatment in any of the assessed 
measures. 
Titration 
The proportion of participants who were titrated did not differ between the LT group (n = 9; 
40.9%) and the placebo group (n = 9; 39.1%), results NS. On the HAMA, participants titrated 
in the LT group had a higher baseline (Week 0) to endpoint (Week 8) change score (-5.89 ± 
4.76) compared to participants not titrated (-3.92 ± 6.75). However, this effect was not 
significant, F(1, 20) = 0.57, p = 0.46. Excluding participants who were titrated did not 
markedly alter results of above LMMs for the HAMA, ISI, BAI, MADRS, or scores on the trail 
making test and emotional Stroop. 
Adverse events (AEs)
There was no significant difference in AEs (measured on the SAFTEE) between placebo and 
LT groups, t(41) = 0.32, p = 0.75. The most commonly reported adverse events on the 
SAFTEE were sleep disturbance (active = 11, placebo = 15), drowsiness (active = 11, placebo 
= 11), weakness/fatigue (active = 9, placebo = 13), irritability (active = 9, placebo = 11), 
trouble concentrating (active = 7, placebo = 11) and gastrointestinal discomfort (active = 7, 
placebo = 10). No adverse events were significantly more common in either group. After 
incorporating SAFTEE severity scores of each item (measured on a scale of 1-4), however, 
the placebo group reported significantly worse sleep disturbance as an adverse event than LT, 
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t(27) = 2.22, p = 0.035. There were no differences in reported adverse events between LT 
participants who were titrated and those who were not. 
DISCUSSION
To our knowledge this was the first study investigating the use of adjunctive L-theanine in the 
treatment of anxiety and sleep disturbance in GAD. While LT did not demonstrate any 
beneficial effect over placebo on measures of anxiety, mood, worry or cognition, there was 
indication that LT may improve self-reported sleep satisfaction in GAD, and insomnia 
symptoms overall in a subset of individuals with GAD. This tentative association was supported 
by a significant treatment effect of LT on the sleep satisfaction item of the ISI, as well as a 
significant Group x Time interaction in individuals who did not meet threshold criteria for 
clinical insomnia (as described by the ISI). As such, LT may have a particular benefit in 
improving sleep in individuals with mild insomnia symptoms. The efficacy of LT in insomnia 
was also supported by more severe ‘sleep disturbance’ recorded as an adverse event in the 
placebo group relative to LT. It is noted, however, that no separation by treatment was 
observed in the analysis of the complete sample on the ISI and that subgroup analyses of 
such modest sample size (n=25), are susceptible to type II error (although the observed p 
value did indicate a highly significant interaction). As no correlation between change in ISI 
score and change in HAMA score across the trial was noted in the LT group, this effect of LT 
does not appear to be secondary to any effect on anxiety. However, individuals who had lower 
baseline HAMA scores were more responsive on the ISI, indicating that response may also 
depend on baseline anxiety severity. As such, LT may potentially have been efficacious in 
improving mild insomnia symptoms as these symptoms are relatively less entangled with 
severe symptoms of anxiety. Interestingly, this suggests that LT may offer similar (or 
potentially greater) efficacy in non-anxious populations experiencing insomnia (particularly of 
sub-clinical severity). This potentiality is also highlighted by recent developments in insomnia 
research which suggest that insomnia should not be considered a ‘primary’ or ‘secondary’ 
disorder as such, as little evidence suggests that insomnia comorbid with psychiatric illness is 
qualitatively different to that which is not (Stepanski and Rybarczyk, 2006).
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Observed results are supported by a previous RCT in 93 children which demonstrated an LT 
related improvement to sleep quality (not observed on parent-reported sleep reports) (Lyon 
et al., 2011), as well as an open label trial which demonstrated improvement in PSQI scores 
in 20 participants with MDD (Hidese et al., 2016). A further open label study in 17 patients 
with schizophrenia has reported improvements in subjective sleep quality (as per the PSQI) 
after 8-week of LT (250mg/day) supplementation (Ota et al., 2015). Additionally, LT has been 
shown to partially reverse the effects of caffeine-induced sleep disturbance in a rat model, 
providing further evidence for LT’s therapeutic potential in insomnia (Jang et al., 2012). 
Anxiolytic and anti-stress effects of LT have been reported in a non-clinical population of 
pharmacy students (Unno et al., 2013b), and an open label (n=20) depression study 
(250mg/day adjunctive to antidepressants) (Hidese et al., 2016). Further, a 2-week RCT 
(n=60) investigation of LT in schizophrenia (400mg/day, adjunctive to antipsychotics) found 
significant anxiolytic effects, although it is uncertain whether the separation observed in this 
study was more related to differences in baseline score than response to treatment (as 
response slopes show little observable separation; and the data is not clearly reported) 
(Ritsner et al., 2011). The current study did not replicate these previous, positive findings. 
While LT may be an efficacious treatment option in sub-clinical anxiety, or anxiety which is 
secondary to other conditions, as previous studies have reported, our study has found lack of 
benefit in primary GAD. This is in line with the findings of Lu et al., (2004) who failed to find 
an acute effect of LT on anticipatory anxiety when compared to alprazolam and a placebo.
Overall, LT was very well tolerated, with no serious adverse events noted. It is however worth 
noting that there is evidence suggesting the therapeutic effects of LT reaches a plateau at 
400mg/day, whereas our study had titrated the dose up to 900mg/day. One particular study 
found the use of LT at 200mg/day and 400mg/day, but not 600mg/day, increased 
sensorimotor gating in 14 healthy controls (Ota et al., 2015). Sensorimotor gating is thought 
to be disrupted in certain psychiatric disorders such as anxiety and schizophrenia and is the 
process of filtering unnecessary stimuli in the brain (Ota et al., 2014). Further, the Jang et al. 
ACCEPTED MANUSCRIPT
 12
(2012) rat model found low doses of LT, not higher doses, counteracted the effects of caffeine-
induced sleep disturbance. These findings need to be considered with caution, as they were 
conducted in small, non-clinical and animal samples and this may not be generalisable to our 
clinical study population. In the current study, patients who were titrated to a doubled dose 
of LT (900mg) were no more likely to experience adverse events than those who were not 
titrated. They also had a higher baseline to endpoint change score compared to the 
participants not titrated, albeit this effect was non-significant. This suggests that a higher 
dose of 900mg/day may improve the response for some participants such as in cases of non-
response. It is also worth considering that a longer duration at 450mg/day may have shown 
a treatment effect and optimal dosing should be investigated in future studies. 
Several strengths of this study are noted, including its double-blind, placebo-controlled 
design, thoroughly considered and implemented inclusion and exclusion criteria, and the use 
of a non-treatment one week ‘run-in’ period. A modest sample size is however recognized as 
a limitation. Secondly, pertinent covariates, such as type, and dose of antidepressant could 
not be adequately investigated for due to limitations in statistical power. The significant 
difference in psychotherapy treatment between the two groups may have had an impact on 
outcomes, with the LT group potentially being more challenging to treat (due to non-response 
to both antidepressant and psychological therapy, and a higher mean age). Finally, we 
acknowledge the lack of objective measurement of sleep as an additional limitation of the 
study, and suggest the use of actigraphy or polysomnography, as appropriate, to explore the 
effect of LT on objective sleep parameters in further studies. Finally, it is worth noting that 
the non-specific dosing instructions provided to participants, may have created 
pharmacokinetic variations depending on whether the LT was taken with or away from food 
or beverages.  
In conclusion, while this preliminary pilot study found no evidence to support the efficacy of 
adjunctive LT in the treatment of anxiety in GAD, LT may improve sleep satisfaction, as well 
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as symptoms of sleep disturbance in cases of mild insomnia. A larger study focusing on 
insomnia as the primary outcome is required to validate this finding.
References
Beck, A.T., Epstein  Brown, G., N., Steer, R.A., 1988. An inventory for measuring clinical 
anxiety: Psychometric properties. J Consult Clin Psychol 56, 893–897.
Carpenter, J.K., Andrews, L.A., Witcraft, S.M., Powers, M.B., Smits, J.A.J., Hofmann, S.G., 
2018. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of 
randomized placebo-controlled trials. Depress. Anxiety. 
https://doi.org/10.1002/da.22728
Cox, R.C., Olatunji, B.O., 2016. A systematic review of sleep disturbance in anxiety and 
related disorders. J. Anxiety Disord. https://doi.org/10.1016/j.janxdis.2015.12.001
Ferre Navarrete, F., Pérez Páramo, M., Fermin Ordoño, J., López Gómez, V., 2017. 
Prevalence of Insomnia and Associated Factors in Outpatients With Generalized Anxiety 
Disorder Treated in Psychiatric Clinics. Behav. Sleep Med. 15, 491–501. 
https://doi.org/10.1080/15402002.2016.1163703
Hamilton, M., 1959. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32, 50–
55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
Hidese, S., Ota, M., Wakabayashi, C., Noda, T., Ozawa, H., Okubo, T., Kunugi, H., 2016. 
Effects of chronic l-theanine administration in patients with major depressive disorder: 
an open-label study. Acta Neuropsychiatr 1–8. https://doi.org/10.1017/neu.2016.33
Jang, H.S., Jung, J.Y., Jang, I.S., Jang, K.H., Kim, S.H., Ha, J.H., Suk, K., Lee, M.G., 2012. 
L-theanine partially counteracts caffeine-induced sleep disturbances in rats. Pharmacol. 
Biochem. Behav. 101, 217–221. https://doi.org/10.1016/j.pbb.2012.01.011
Kakuda, T., Hinoi, E., Abe, A., Nozawa, A., Ogura, M., Yoneda, Y., 2008. Theanine, an 
ingredient of green tea, inhibits [3H] glutamine transport in neurons and astroglia in rat 
brain. J. Neurosci. Res. 86, 1846–1856. https://doi.org/10.1002/jnr.21637
Kimura, R., Murata, T., 1971. Influence of alkylamides of glutamic acid and related 
compounds on the central nervous system. I. Central depressant effect of theanine. 
Chem. Pharm. Bull. (Tokyo). 19, 1257–61.
Lardner, A.L., 2014. Neurobiological effects of the green tea constituent theanine and its 
potential role in the treatment of psychiatric and neurodegenerative disorders. Nutr. 
Neurosci. 17, 145–155. https://doi.org/10.1179/1476830513Y.0000000079
Latas, M., Trajković, G., Bonevski, D., Naumovska, A., Latas, D.V., Bukumirić, Z., Starčević, 
ACCEPTED MANUSCRIPT
 14
V., 2018. Psychiatrists&apos; treatment preferences for generalized anxiety disorder. 
Hum. Psychopharmacol. Clin. Exp. 33. https://doi.org/10.1002/hup.2643
Levine, J., Schooler, N.R., 1986. SAFTEE: a technique for the systematic assessment of side 
effects in clinical trials. Psychopharmacol. Bull. 22, 343–81. 
https://doi.org/10.1093/jnci/djm189
Lu, K., Gray, M.A., Oliver, C., Liley, D.T., Harrison, B.J., Bartholomeusz, C.F., Phan, K.L., 
Nathan, P.J., 2004. The acute effects of L-theanine in comparison with alprazolam on 
anticipatory anxiety in humans. Hum. Psychopharmacol. 
https://doi.org/10.1002/hup.611
Lyon, M., Kapoor, M., Juneja, L., 2011. The Effects of L-Theanine (Suntheanine® ) on 
Objective Sleep Quality in Boys with Attention Deficit Hyperactivity Disorder (ADHD): a 
Randomized, Double-blind, Placebo-controlled Clinical Trial. Altern. Med. Rev. 16, 348–
354.
Meyer, T.J., Miller, M.L., Metzger, R.L., Borkovec, T.D., 1990. Development and validation of 
the penn state worry questionnaire. Behav. Res. Ther. https://doi.org/10.1016/0005-
7967(90)90135-6
Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to 
change. Br. J. Psychiatry 134, 382–9.
Morin, C.M., Belleville, G., Bélanger, L., Ivers, H., 2011. The Insomnia Severity Index: 
Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response. 
Sleep 34, 601–608. https://doi.org/10.1093/sleep/34.5.601
Ogawa, S., Ota, M., Ogura, J., Kato, K., Kunugi, H., 2018. Effects of l-theanine on anxiety-
like behavior, cerebrospinal fluid amino acid profile, and hippocampal activity in Wistar 
Kyoto rats. Psychopharmacology (Berl). https://doi.org/10.1007/s00213-017-4743-1
Ota, M., Wakabayashi, C., Sato, N., Hori, H., Hattori, K., Teraishi, T., Ozawa, H., Okubo, T., 
Kunugi, H., 2015. Effect of L-theanine on glutamatergic function in patients with 
schizophrenia. Acta Neuropsychiatr 27, 291–296. https://doi.org/10.1017/neu.2015.22
Reinhold, J.A., Mandos, L.A., Rickels, K., Lohoff, F.W., 2011. Pharmacological treatment of 
generalized anxiety disorder. Expert Opin Pharmacother 12, 2457–2467. 
https://doi.org/10.1517/14656566.2011.618496
Reinhold, J.A., Rickels, K., 2015. Pharmacological treatment for generalized anxiety disorder 
in adults: an update. Expert Opin Pharmacother 16, 1669–1681. 
https://doi.org/10.1517/14656566.2015.1059424
ACCEPTED MANUSCRIPT
 15
Ritsner, M.S., Miodownik, C., Ratner, Y., Shleifer, T., Mar, M., Pintov, L., Lerner, V., 2011. L-
theanine relieves positive, activation, and anxiety symptoms in patients with 
schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, 
placebo-controlled, 2-center study. J Clin Psychiatry 72, 34–42. 
https://doi.org/10.4088/JCP.09m05324gre
Sarris, J., Kavanagh, D.J., Byrne, G., 2010. Adjuvant use of nutritional and herbal medicines 
with antidepressants, mood stabilizers and benzodiazepines. J. Psychiatr. Res. 
https://doi.org/10.1016/j.jpsychires.2009.06.003
Sarris, J., Murphy, J., Mischoulon, D., Fava, M., Berk, M., Ng, C., 2016. Adjunctive Nutrient 
Nutraceuticals for Depression: A Systematic Review and Meta-analyses. Am. J. 
Psychiatry 173, 575–587.
Schallier, A., Vermoesen, K., Loyens, E., Van Liefferinge, J., Michotte, Y., Smolders, I., 
Massie, A., 2013. <scp>l</scp> -Theanine intake increases threshold for limbic seizures 
but decreases threshold for generalized seizures. Nutr. Neurosci. 
https://doi.org/10.1179/1476830512Y.0000000033
Shen, H., Shen, X., Wang, R., Wu, M., 2011. [Effects of theanine on cerebral ischemia-
reperfusion injury in rats]. Wei Sheng Yan Jiu 40, 684–687.
Stepanski, E.J., Rybarczyk, B., 2006. Emerging research on the treatment and etiology of 
secondary or comorbid insomnia. Sleep Med. Rev. 
https://doi.org/10.1016/j.smrv.2005.08.002
Syu, K.-Y., Lin, C.-L., Huang, H.-C., Lin, J.-K., 2008. Determination of Theanine, GABA, and 
Other Amino Acids in Green, Oolong, Black, and Pu-erh Teas with Dabsylation and High-
Performance Liquid Chromatography. J. Agric. Food Chem. 56, 7637–7643. 
https://doi.org/10.1021/jf801795m
The WHOQOL GROUP, 1998. Development of the World Health Organization WHOQOL-BREF 
Quality of Life Assessment. Psychol. Med. Cambridge Univ. Press 28, 551–558.
Unno, K., Iguchi, K., Tanida, N., Fujitani, K., Takamori, N., Yamamoto, H., Ishii, N., Nagano, 
H., Nagashima, T., Hara, A., Shimoi, K., Hoshino, M., 2013a. Ingestion of theanine, an 
amino acid in tea, suppresses psychosocial stress in mice. Exp. Physiol. 98, 290–303. 
https://doi.org/10.1113/expphysiol.2012.065532
Unno, K., Tanida, N., Ishii, N., Yamamoto, H., Iguchi, K., Hoshino, M., Takeda, A., Ozawa, 
H., Ohkubo, T., Juneja, L.R., Yamada, H., 2013b. Anti-stress effect of theanine on 
students during pharmacy practice: Positive correlation among salivary alpha-amylase 
activity, trait anxiety and subjective stress. Pharmacol. Biochem. Behav. 111, 128–135. 
ACCEPTED MANUSCRIPT
 16
https://doi.org/10.1016/j.pbb.2013.09.004
Wakabayashi, C., Numakawa, T., Ninomiya, M., Chiba, S., Kunugi, H., 2012. Behavioral and 
molecular evidence for psychotropic effects in L-theanine. Psychopharmacology (Berl). 
219, 1099–1109. https://doi.org/10.1007/s00213-011-2440-z
Yamada, T., Terashima, T., Okubo, T., Juneja, L.R., Yokogoshi, H., 2005. Effects of theanine, 
r-glutamylethylamide, on neurotransmitter release and its relationship with glutamic 
acid neurotransmission. Nutr. Neurosci. 8, 219–226. 
https://doi.org/10.1080/10284150500170799
Yamada, T., Terashima, T., Wada, K., Ueda, S., Ito, M., Okubo, T., Juneja, L.R., Yokogoshi, 
H., 2007. Theanine, r-glutamylethylamide, increases neurotransmission concentrations 
and neurotrophin mRNA levels in the brain during lactation. Life Sci. 81, 1247–1255. 
https://doi.org/10.1016/j.lfs.2007.08.023
ACCEPTED MANUSCRIPT
Conflict of interest
J.Sarris has received either presentation honoraria, travel support, clinical trial grants, book royalties, 
or independent consultancy payments from: Integria Healthcare & MediHerb, Pfizer, Scius Health, Key 
Pharmaceuticals, Taki Mai, FIT-BioCeuticals, Blackmores, Soho-Flordis, Healthworld, HealthEd, 
HealthMasters, Kantar Consulting, Research Reviews, Elsevier, Chaminade University, International 
Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, 
Society for Medicinal Plant and Natural Product Research, Sanofi-Aventis, Omega-3 Centre, the National 
Health and Medical Research Council, CR Roper Fellowship. CN had served in the Servier, Lundbeck, 
Janssen-Cilag, Wyeth and Eli Lilly Advisory Boards, received research grant support from Wyeth and 
Lundbeck, and speaker honoraria from Servier, Lundbeck, Bristol-Myers Squibb, Organon, Eli Lilly, 
GlaxoSmithKline, Janssen- Cilag, Astra-Zenaca, Wyeth, and Pfizer.
Contributors 
Author Sarris designed the study. Authors Sarris, Byrne, Ng, and Menon contributed to the design and 
write-up of the protocol. Authors Sarris, Cribb and Birling designed and implemented the statistical 
analysis. Authors Murphy, Cribb, Karamacoska, Galea, Short, MacDonald, Nazareth, and Oliver were 
involved in the data collection and entry. All authors have contributed to and approved the final 
manuscript. 
Acknowledgements
JS is supported by an NHMRC Clinical Research Fellowship (APP 1125000). The study was co-
sponsored by FIT-BioCeuticals. No funding source was involved in the design, statistical analysis or 
preparation of this manuscript. Study sponsors similarly played no role in the decision to submit this 
manuscript for publication. 
ACCEPTED MANUSCRIPT
Figure 1. CONSORT Flow Diagram 
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Figure 2. HAMA score during treatment and post-treatment observation period in LT (n = 22) and 
placebo (n = 24) groups. 
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HAMA = Hamilton anxiety rating scale (p = 0.38); Showing treatment period from week 1 (pre-
randomisation visit) to week 8 (completion). Mean scores represent estimated marginal means derived 
from unadjusted linear mixed effects models. Error bars represent 95% confidence interval of estimated 
mean HAMA score at each time point. 
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Figure 3. Sleep quality on the ISI in placebo (n = 24) and LT (n = 22) groups
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ISI- Insomnia Severity Index results (p = 0.35). Mean scores represent estimated marginal means from 
unadjusted linear mixed-effects models; Error bars represent confidence interval of estimated mean ISI 
scores.   
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Table 1. Demographic and clinical characteristics
Characteristics Treatment (n=22) Placebo (n=24)
Age, mean (SD) 40.7 (15.0) 32.2 (9.29)
Female gender, % (n) 81.8 (18) 87.5 (21)
Years of Education, mean (SD) 15.6 (1.94) 15.1 (2.85)
Married/defacto, % (n) 63.6 (14) 58.3 (14)
Employed/student1, % (n) 77.3 (17) 91.6 (22)
Health/comorbidity
BMI, mean (SD) 25.5 (5.16) 27.4 (5.44)
Alcohol consumption, mean (SD)/week      3.51 (3.31) 3.26 (4.39)
Panic disorder, % (n) 31.8 (7) 16.7 (4)
Agoraphobia, % (n) 36.4 (8) 34.8 (8)
Social phobia, % (n) 13.6 (3) 16.7 (4)
WHOQOL domains, mean (SD)
Physical 50.0 (10.3) 52.9 (9.90)
Psychological 50.2 (9.14) 52.3 (13.8)
Social relations 58.7 (13.0) 57.2 (19.5)
Environment 72.0 (13.4) 70.3 (14.9) 
Treatment, % (n)
Medication type
SSRI 72.7 (16) 70.8 (17)
SNRI 13.6 (3) 20.8 (5)
Other 13.6 (3) 8.30 (2)
Current psychotherapy 72.7 (16) 34.8 (8)
1Full or part time; BMI= body mass index; WHOQOL= World Health Organisation Quality of Life Assessment; SSRI= Serotonin 
Specific Reuptake Inhibitor; SNRI= Serotonin Norepinephrine Reuptake Inhibitor; Alcohol consumption= Standardised Units per 
week
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  Table 2. Mean baseline scores and change across time for each measure 
Measure Baseline, mean (SD) End point (week 8), mean (95% 
CI)*
Statistic1 
Placebo Active Placebo Active
HAMA 20.5 
(4.98)
21.9 (4.01) 14.3 (11.6, 
16.9)
15.5 (12.9, 18.1) F(1,162) = 0.782, p = .38
MADRS 11.9 
(3.86)
12.9 (2.85) 9.17 (6.86, 
11.5)
11.3 (9.08, 13.5) F(1,162) = 0.305, p = .58
PSWQ 62.8 
(12.2)
63.0 (10.5) 57.6 (52.4, 
62.8)
58.2 (52.9, 63.5) F(1,152) = .010, p= .92
BAI 20.3 
(9.11)
25.3 (9.58) 10.9 (7.17, 
14.6)
12.6 (8.93, 16.2) F(1,153) = 0.815, p=.37
ISI 10.9 
(7.12)
11.7 (6.05) 10.6 (7.66, 
13.5)
9.72 (6.79, 12.6) F(1,47) = 0.856, p = .35
HAMA – Hamilton Anxiety Rating Scale; MADRS – Montgomery-Asberg Depression Rating Scale; PSWQ – Penn State Worry 
Questionnaire; BAI – Beck Anxiety Inventory; ISI – Insomnia Severity Index; *Estimated marginal means derived from LMM; 
1Group x Time interaction effect from linear mixed effects model.
